Surmodics, Inc. (SRDX) News

Surmodics, Inc. (SRDX): $27.90

1.22 (+4.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SRDX News Items

SRDX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SRDX News Highlights

  • SRDX's 30 day story count now stands at 8.
  • Over the past 25 days, the trend for SRDX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DRUG and PATH are the most mentioned tickers in articles about SRDX.

Latest SRDX News From Around the Web

Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.

SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?

SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | January 24, 2023

Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update

Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.

Yahoo | January 23, 2023

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently

Wallstreet:Online | January 19, 2023

Surmodics Stock Slides Following Regulatory Setback For Its SurVeil Drug-Coated Balloon

Surmodics Inc (NASDAQ: SRDX) has received a letter from the FDA related to its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently approvable while providing specific guidance on a path forward. The letter stated that certain information within two general categories—biocompatibility and labeling—must be added by an amendment to the company's PMA application to place it in approvable form. Although

Yahoo | January 19, 2023

Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

EDEN PRAIRIE, Minn., January 19, 2023--The Sundance™ SCB delivers drug to target tissue via a coating of stable crystalline sirolimus with a proprietary excipient on the balloon surface.

Yahoo | January 19, 2023

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn., January 19, 2023--Surmodics received a letter from the FDA that indicated that the PMA application for the SurVeil™ drug-coated balloon is not currently approvable.

Yahoo | January 19, 2023

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

EDEN PRAIRIE, Minn., January 16, 2023--Professor Varcoe will present data from the SWING Trial, a FIH study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon.

Yahoo | January 16, 2023

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Yahoo | December 30, 2022

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SurModics (SRDX – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments. SurModics (SRDX) In a report released today, Michael Petusky from Barrington maintained a Buy rating on SurModics, with a price target of $70.00. The company's shares closed last Thursday at $32.86. According to TipRanks.

Christine Brown on TipRanks | November 18, 2022

Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn., November 17, 2022--Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

Yahoo | November 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6061 seconds.